Highlights Cybin Inc.

Equities

CLXPF

CA23256X4075

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:00 2024-12-12 pm EST			5-day change	1st Jan Change
10.04 ^USD	-2.33%		-3.74%	-35.56%

Dec. 11	Cybin Inc. - Special Call
Nov. 18	Cybin Says Phase 2 Data Show Potential Depression Drug Offers Relief Through 1 Year	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cybin Says Phase 2 Data Show Potential Depression Drug Offers Relief Through 1 Year	Nov. 18	MT
Cybin Reports Positive Phase 2 Data for Cyb003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder	Nov. 18	CI
Cybin Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024	Nov. 13	CI
Cybin Initiates PARADIGM Multinational Pivotal Phase 3 Program Evaluating Cyb003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results	Nov. 13	CI
Cybin Inc. Provides Corporate Update on Upcoming Clinical Milestones	Sep. 20	CI
Cybin to Begin Phase 3 Trial of Treatment for Major Depressive Disorder This Summer	Aug. 13	MT
Cybin Inc. Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder	Aug. 13	CI
Cybin Inc. Reports Earnings Results for the First Quarter Ended June 30, 2024	Aug. 08	CI
Cybin Inc. Reports Earnings Results for the Full Year Ended March 31, 2024	Jun. 26	CI
Cybin Provides Corporate Provides Update Highlighting Recent Clinical Accomplishments and Key Upcoming Catalysts Across Its Development Pipeline	May. 06	CI
Cybin Secures US Patent for CYB003 Program in Major Depressive Disorder Treatment	Apr. 16	MT
Cybin Inc. Initiates Phase 2 Proof-Of-Concept Study of Cyb004 in Generalized Anxiety Disorder	Mar. 15	CI
Cybin Reaches Alignment With FDA on Late-Stage Design For Major Depressive Disorder Trial	Mar. 14	MT
Cybin Inc. Announces Positive End-Of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design	Mar. 14	CI
Cybin Inc. Receives FDA Breakthrough Therapy Designation for Its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder	Mar. 13	CI
Cybin Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 14	CI
Cybin Gets FDA Clearance for Generalized Anxiety Disorder Study	Jan. 23	MT
Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder	Jan. 23	CI
Cybin Inc. Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028	Jan. 08	CI
Cybin Inc. Announces Recent Positive Phase 2 CYB003 Topline Results in MDD and Outlines Key Upcoming Milestones Across its Clinical Development Programs	Jan. 04	CI
Cybin Inc. Announces the Presentation of Four Posters At the American College of Neuropsychopharmacology Annual Meeting	Dec. 06	CI
Cybin Inc. Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses	Nov. 30	CI
Cybin Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 13	CI
Cybin Inc. Provides Update on its Clinical-Stage Programs and Key Upcoming Milestones Across its Development Pipeline	Nov. 01	CI
Cybin Inc. Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose	23-10-31	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cybin Inc.

Equities

CLXPF

CA23256X4075

Biotechnology & Medical Research

Highlights

Filters